Read by QxMD icon Read

Journal of Thoracic Oncology

Thibaut Lizée, Ethan Basch, Pierre Trémolières, Eric Voog, Julien Domont, Guillaume Peyraga, Thierry Urban, Jaafar Bennouna, Anne-Lise Septans, Magali Balavoine, Bruno Detournay, Fabrice Denis
BACKGROUND: A multicenter randomized clinical trial in France found an overall survival benefit of web-based patient-reported outcome (PRO)-based surveillance following initial treatment for lung cancer compared with conventional surveillance. The aim of this study was to assess the cost-effectiveness of this PRO-based surveillance in lung cancer patients. METHODS: This medico-economic analysis employed data from the clinical trial, augmented by abstracted chart data and costs of consultations, imaging, transportations, information technology, and treatments...
February 15, 2019: Journal of Thoracic Oncology
Reenika Aggarwal, Andrew Cl Lam, Maureen McGregor, Ravi Menezes, Katrina Hueniken, Hannah Tateishi, Grainne M O'Kane, Ming Sound Tsao, Frances A Shepherd, Wei Xu, Micheal McInnis, Heidi Schmidt, Geoffrey Liu, John Kavanagh
HYPOTHESIS: We hypothesize that the incidence of screen-detected lung cancer (LC), in participants with previously negative scans, will be highest in the cohort with the highest baseline risk score. METHODS: Individuals with negative baseline screening results from the Princess Margaret International Early Lung Cancer Action Program prior to 2009 underwent low-dose CT rescreening from 2015 to 2018. Individuals were contacted in order of descending risk, as determined by the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial's PLCOM2012 6-year LC risk-prediction model, and then categorized into three risk cohorts according to their baseline risks...
February 13, 2019: Journal of Thoracic Oncology
Wei-Hsun Hsu, Xiaoliang Zhao, Jianquan Zhu, In-Kyu Kim, Guanhua Rao, Justine McCutcheon, Shuo-Tse Hsu, Beverly Teicher, Bhaskar Kallakury, Afshin Dowlati, Yu-Wen Zhang, Giuseppe Giaccone
INTRODUCTION: Platinum-based chemotherapy remains the standard treatment for patients with small cell lung cancer (SCLC), but the benefit of the treatment is often hampered by rapid development of drug resistance. Thus far, there is no targeted therapy available for SCLC. Over 90% of SCLC tumors harbor mutations in the tumor suppressor gene p53, an important DNA damage checkpoint regulator, and these tumor cells rely predominantly on the checkpoint kinases to control DNA damage response...
February 13, 2019: Journal of Thoracic Oncology
Jong Woo Lee, Yu Zhang, Kyung Jin Eoh, Roshan Sharma, Miguel F Sanmamed, Jenny Wu, Justin Choi, Hee Sun Park, Akiko Iwasaki, Edward Kaftan, Lieping Chen, Vali Papadimitrakopoulou, Roy S Herbst, Ja Seok Koo
PURPOSE: To characterize the tumor-infiltrating immune cells population in Kras/p53-driven lung tumors and to evaluate the combinatorial anti-tumor effect with MEK inhibitor (MEKi), trametinib, and immunomodulatory monoclonal antibodies (mAbs) targeting either programmed cell death protein-1 (PD-1) or programmed cell death protein ligand 1 (PD-L1) in vivo. EXPERIMENTAL DESIGN: Trp53FloxFlox ;KrasG12D/+ ;Rosa26LSL-Luciferase/LSL-Luciferase (PKL) genetically engineered mice were utilized to develop autochthonous lung tumors with intratracheal delivery of adenoviral Cre recombinase...
February 13, 2019: Journal of Thoracic Oncology
Patrick Robelin, Julien Hadoux, Julien Forestier, David Planchard, Valérie Hervieu, Amandine Berdelou, Jean-Yves Scoazec, Pierre-Jean Valette, Sophie Leboulleux, Michel Ducreux, Catherine Lombard-Bohas, Eric Baudin, Thomas Walter
INTRODUCTION: Metastatic lung carcinoids (MLC) remain poorly characterized and no prognostic stratification exists. METHODS: We conducted a retrospective study including patients with MLC in two European expert centers. The aims were to characterize these, identify prognostic factors of survival, and effectiveness of their treatments. RESULTS: A total of 162 patients with MLC were included: 50% were women, and median age was 61 years. Half of patients had synchronous metastases, mainly located in the liver (75%), bone (42%), and lung (25%)...
February 13, 2019: Journal of Thoracic Oncology
Zhihua Gong, Qingzhu Jia, Junying Chen, Xinwei Diao, Jianbao Gao, Xinxin Wang, Bo Zhu
INTRODUCTION: Whether the efficacy of PD-1/PD-L1 inhibitors declines with senescence remains controversial for lung adenocarcinoma (LUAD). Responsiveness to anti-PD-1/PD-L1 therapy is thought to rely on neoantigen exposure and immune elements in the tumor microenvironment. In this study, we explored the features of the tumor immune microenvironment in elderly patients with treatment-naïve LUAD. METHODS: Transcriptome profiles and clinical characteristics of patients with LUAD were retrieved from TCGA as a discovery cohort...
February 12, 2019: Journal of Thoracic Oncology
James Chih-Hsin Yang, Frances A Shepherd, Dong-Wan Kim, Gyeong-Won Lee, Jong Seok Lee, Gee-Chen Chang, Sung Sook Lee, Yu-Feng Wei, Yun Gyoo Lee, Gianluca Laus, Barbara Collins, Francesca Pisetzky, Leora Horn
INTRODUCTION: Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). Durvalumab is an anti-PD-L1 monoclonal antibody. The Phase III open-label CAURAL trial (NCT02454933) investigated osimertinib plus durvalumab versus osimertinib monotherapy in patients with EGFR-TKI sensitizing and T790M mutation-positive advanced non-small cell lung cancer (NSCLC) and disease progression following EGFR-TKI therapy. METHODS: Patients were randomly assigned 1:1 to receive oral osimertinib (80 mg once daily) with/without durvalumab (10 mg/kg intravenously every two weeks), until progression...
February 11, 2019: Journal of Thoracic Oncology
Stefan Zimmerman, Arundhati Das, Shuhang Wang, Ricklie Julian, Leena Gandhi, Juergen Wolf
Small cell lung cancer remains an aggressive, deadly cancer with only modest effect on survival from standard chemotherapy. However, with the advent of immunotherapy and comprehensive genomic and transcriptomic profiling, multiple new targets are showing promise in the clinical arena, and just recently PD-L1 inhibition has been shown to improve the efficacy of standard chemotherapy in extended disease SCLC. Our increasing understanding of the interactions between different pathways will enable more tailored immuno- as well as targeted therapies based on specific biomarkers and rational combinations...
February 11, 2019: Journal of Thoracic Oncology
Arnaud Jeanson, Pascale Tomasini, Maxime Souquet-Bressand, Nicolas Brandone, Mohamed Boucekine, Mathieu Grangeon, Solène Chaleat, Natalyia Khobta, Julie Milia, Laurent Mhanna, Laurent Greillier, Julie Biemar, Isabelle Nanni, L'houcine Ouafik, Stéphane Garcia, Julien Mazières, Fabrice Barlesi, Céline Mascaux
INTRODUCTION: KRAS mutation (KRASm) is the most frequent molecular alteration found in advanced non-small cell lung cancer (NSCLC), is associated with a poor prognosis, without available targeted therapy. Treatment options for NSCLC have been recently enriched by the development of immune checkpoint inhibitors (ICI), and data about its efficacy in patients with KRASm NSCLC are discordant. This study assessed the routine efficacy of ICI in advanced KRASm NSCLC. METHODS: In this retrospective study, clinical data were extracted from the medical records of patients with advanced NSCLC treated with ICI and with available molecular analysis between April 2013 and June 2017...
February 6, 2019: Journal of Thoracic Oncology
Badi El Osta, Madhusmita Behera, Sungjin Kim, Lynne D Berry, Gabriel Sica, Rathi N Pillai, Taofeek K Owonikoko, Mark G Kris, Bruce E Johnson, David J Kwiatkowski, Lynette M Sholl, Dara L Aisner, Paul A Bunn, Fadlo R Khuri, Suresh S Ramalingam
BACKGROUND: Mutations in the KRAS gene are the most common driver oncogenes present in lung adenocarcinomas. We analyzed the largest multi-institutional database available containing patients with metastatic KRAS mutant lung adenocarcinomas. METHODS: The Lung Cancer Mutation Consortium (LCMC) is a multi-institutional collaboration to study the genomic characteristics of lung adenocarcinomas, treat them with genomically directed therapeutic approaches, and assess their outcomes...
February 5, 2019: Journal of Thoracic Oncology
Xiaoliang Zhao, Bhaskar Kallakury, Joeffrey J Chahine, Dan Hartmann, YuWen Zhang, Yulong Chen, Hua Zhang, Bin Zhang, Changli Wang, Giuseppe Giaccone
BACKGROUND: Surgery in small cell lung cancer (SCLC) is limited to very early stages, but several reports suggest a potential broader role. Little is known of the influence of microenvironment on the biology of SCLC. METHODS: We assessed the clinical prognostic factors in a large series of resected SCLC patients. The prognostic value of Programmed cell Death Ligand-1 (PD-L1) expression in tumor cells and tumor infiltrating lymphocytes (TILs), and the percentage of CD3, CD20, CD45 and CD68 positive cells, were also investigated...
February 5, 2019: Journal of Thoracic Oncology
Michiel A IJsseldijk, Melina Shoni, Charles Siegert, Bastiaan M Wiering, PhD Md, K C Anton van Engelenburg, Abraham Lebenthal, Richard Pg Ten Broek
INTRODUCTION: SBRT is a promising curative treatment for early-stage NSCLC. IT is unclear if survival outcomes for SBRT are influenced by a lack of pathological confirmation of malignancy and staging of disease in these patients. In this systematic review and meta-analysis we assess survival outcomes after SBRT in studies with patients with clinically diagnosed vs biopsy-proven early-stage NSCLC. METHODS: The main databases were searched for trials and cohort studies without restrictions to publication status or language...
February 2, 2019: Journal of Thoracic Oncology
Audrey Mansuet-Lupo, Marc Barritault, Marco Alifano, Aurélie Janet-Vendroux, Makmoud Zarmaev, Jérôme Biton, Yoan Velut, Christine Le Hay, Isabelle Cremer, Jean-François Régnard, Ludovic Fournel, Bastien Rance, Marie Wislez, Pierre Laurent-Puig, Ronald Herbst, Diane Damotte, Hélène Blons
INTRODUCTION: Multiple nodules in lung are diagnosed with an increasing frequency due to high quality CT-scan imaging. In patients suffering from lung cancer, this situation represents up to 10% of operated patients. For clinical management, it is important to classify the disease as intra-pulmonary metastasis or multiple primary lung carcinomas to define TNM classification and optimize therapeutic options. In the present study, we evaluated the respective and combined input of histological and molecular classification in order to propose a classification algorithm for multiple nodules...
February 2, 2019: Journal of Thoracic Oncology
Xiaofei Wang, Ling Zhou, Jiani C Yin, Xue Wu, Yang W Shao, Beili Gao
No abstract text is available yet for this article.
January 31, 2019: Journal of Thoracic Oncology
F Barlesi, E B Garon, D-W Kim, E Felip, J-Y Han, J-H Kim, M-J Ahn, M J Fidler, M A Gubens, G de Castro, V Surmont, Q Li, A C Deitz, G M Lubiniecki, R S Herbst
BACKGROUND: In the phase 2/3 KEYNOTE-010 study (, NCT01905657), pembrolizumab significantly prolonged overall survival over docetaxel in patients with previously treated, programmed death 1 ligand 1 (PD-L1)-expressing (tumor proportion score [TPS] ≥1%), advanced non-small-cell lung cancer (NSCLC). Health-related quality of life (HRQoL) results are reported here. METHODS: Patients were randomized 1:1:1 to pembrolizumab 2 or 10 mg/kg every 3 weeks (Q3W) or docetaxel 75 mg/m2 Q3W...
January 31, 2019: Journal of Thoracic Oncology
Edward S Kim, Upal Basu Roy, Jennifer L Ersek, Jennifer King, Robert A Smith, Nicole Martin, Renato Martins, Amy Moore, Gerard A Silvestri, James Jett
No abstract text is available yet for this article.
January 29, 2019: Journal of Thoracic Oncology
Rowena Yip, Teng Ma, Raja M Flores, David Yankelevitz, Claudia I Henschke
PURPOSE: To determine long-term survival of visceral pleural invasion (VPI) and parenchymal (PAI: angiolymphatic, vascular) invasion on survival of non-small-cell-lung-cancers (NSCLCs), less than 30 mm in maximum diameter. METHODS: Kaplan-Meier survival for NSCLCs, with and without VPI and/or PAI were determined for a prospective cohort of screening participants, stratified by pathologic tumor size (≤10mm, 11-20mm, and 21-30mm) and nodule consistency. Log-rank test statistics were calculated...
January 24, 2019: Journal of Thoracic Oncology
Martin Reck, Leora Horn, Silvia Novello, Fabrice Barlesi, István Albert, Erzsebet Juhasz, Dariusz Kowalski, Gilles Robinet, Jacques Cadranel, Paolo Bidoli, John Chung, Arno Fritsch, Uta Drews, Andrea Wagner, Ramaswamy Govindan
INTRODUCTION: This Phase II study evaluated the efficacy and safety of the pan-cyclin-dependent kinase inhibitor roniciclib with platinum-based chemotherapy in patients with extensive-disease small-cell lung cancer. METHODS: In this randomized, double-blind study, unselected patients with previously untreated ED-SCLC received roniciclib 5 mg or placebo twice daily in a 3 days on/4 day off schedule in 21-day cycles, with concomitant cisplatin or carboplatin on day 1, and etoposide on days 1-3...
January 21, 2019: Journal of Thoracic Oncology
Chien-Hua Tseng, Ben-Jei Tsuang, Chun-Ju Chiang, Kai-Chen Ku, Jeng-Sen Tseng, Tsung-Ying Yang, Kuo-Hsuan Hsu, Kun-Chieh Chen, Sung-Liang Yu, Wen-Chung Lee, Tsang-Wu Liu, Chang-Chuan Chan, Gee-Chen Chang
INTRODUCTION: For never-smokers (smoked <100 lifetime cigarettes), lung cancer (LC) has emerged as an important issue. We aimed to investigate the effects of prevalence changes in tobacco smoking and particulate matter (PM) 2.5 (PM2.5 ) levels on LC in Taiwan, in relation to contrasting PM2.5 levels, between northern Taiwan (NT) and southern Taiwan (ST). METHODS: We reviewed 371,084 patients with LC to assess smoking prevalence and correlations between the incidence of adenocarcinoma lung cancer (AdLC) and non-AdLC...
January 18, 2019: Journal of Thoracic Oncology
Ibiayi Dagogo-Jack, Marguerite Rooney, Rebecca J Nagy, Jessica J Lin, Emily Chin, Lorin A Ferris, Jennifer Ackil, Jochen K Lennerz, Richard B Lanman, Justin F Gainor, Alice T Shaw
BACKGROUND: Circulating tumor DNA analysis is an emerging genotyping strategy that can identify tumor-specific genetic alterations in plasma including mutations and rearrangements. Detection of ROS1 fusions in plasma requires genotyping approaches that cover multiple breakpoints and target a variety of fusion partners. Compared to other molecular subsets of non-small cell lung cancer (NSCLC), experience with detecting ROS1 genetic alterations in plasma is limited. PATIENTS AND METHODS: To describe the spectrum of ROS1 fusions in NSCLC and determine sensitivity for detecting ROS1 fusions in plasma, we queried the Guardant Health plasma dataset and an institutional tissue database and compared plasma findings to tissue results...
January 18, 2019: Journal of Thoracic Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"